Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Drug Name | Futibatinib |
Trade Name | Lytgobi |
Synonyms | TAS-120 |
Drug Descriptions |
Lytgobi (futibatinib) is a third-generation pan-FGFR inhibitor, which results in the inhibition of FGFR-mediated signal transduction pathways and tumor cell proliferation (PMID: 31109923). Lytgobi (futibatinib) is FDA approved for use in patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 fusion or rearrangement (FDA.gov). |
DrugClasses | FGFR Inhibitor (Pan) 24 |
CAS Registry Number | 1448169-71-8 |
NCIT ID | C114283 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Binimetinib + Futibatinib | Binimetinib Futibatinib | 0 | 1 |
Fulvestrant + Futibatinib | Fulvestrant Futibatinib | 0 | 1 |
Futibatinib | Futibatinib | 122 | 7 |
Futibatinib + Osimertinib | Futibatinib Osimertinib | 0 | 0 |
Futibatinib + Pembrolizumab | Futibatinib Pembrolizumab | 0 | 3 |